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Imaging across the Life Span: 
Innovations in Imaging and 
Therapy for Gynecologic Cancer1
The focus of this article is radiation therapy for gynecologic can-
cers, with emphasis on imaging-based treatment planning and 
delivery. For the various gynecologic cancers, radiation oncologists 
rely on essential clinical information to triage treatment options, 
and various imaging studies are performed for treatment planning 
and radiation therapy delivery. A practical approach is provided to 
help radiologists tailor their reports for the needs of their radiation 
oncology and gynecologic oncology colleagues, to optimize mul-
tidisciplinary care for patients with gynecologic cancer. Template 
radiology reports are proposed to address the specific information 
needs of oncologists at each phase—before, during, and after treat-
ment. Fueled by the rapid progress in engineering and computer 
sciences during the past 2 decades, remarkable advances have been 
made in anatomic, functional, and molecular imaging and in radia-
tion treatment planning and delivery in patients with gynecologic 
cancer. Radiation therapy has evolved from a nontargeted approach 
to a precisely targeted, highly conformal treatment modality, to 
further improve treatment outcomes and reduce morbidity. High-
quality imaging has become essential for staging of the disease, de-
lineation of tumor extent for treatment planning and delivery, and 
monitoring therapy response. Anatomic and functional imaging has 
also been shown to provide prognostic information that allows clini-
cians to tailor therapy on the basis of personalized patient informa-
tion. This field is an area of active research, and future clinical trials 
are warranted to validate preliminary results in the field.
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After completing this journal-based SA-
CME activity, participants will be able to:
 ■ Describe the role of radiation therapy 
in patients with gynecologic cancer.
 ■ Explain the role of imaging in pretreat-
ment evaluation and radiation therapy 
planning for gynecologic cancer.
 ■ Describe the use of advanced imaging 





Gynecologic cancer remains an important health problem for 
women worldwide. Uterine cancer is the most common gynecologic 
malignancy in the Western world, including the United States, and 
is the second most common cause of deaths from gynecologic can-
cer (1). The incidence of and mortality from cervical cancer have 
decreased steadily in the Western world during the past 5 decades 
with the implementation of successful screening programs. Cervical 
cancer continues to be one of the most common and fatal cancers in 
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therapy for (a) the evaluation of the extent of 
tumor involvement for pretherapy staging and 
prognostic assessment, (b) tumor delineation for 
targeting in radiation therapy planning, (c) the 
evaluation of therapy response after or during 
the course of treatment, and (d) the prediction 
of early response and outcome, an emerging role 
that enables potential adaptive treatment.
The purpose of this article is to encourage 
radiologists to provide high-quality imaging and 
radiology reports to facilitate collaboration with 
radiation oncologists and gynecologic oncolo-
gists, to provide optimum care for patients with 
gynecologic cancer. First, the types of radiation 
therapy for gynecologic cancer are reviewed, 
followed by the imaging modalities for pretreat-
ment staging and prognosis. Then the principles 
of therapy and the role of imaging are covered 
for various types of gynecologic cancers, fol-
lowed by the role of multimodality imaging in 
radiation therapy. Finally, the use of imaging for 
early response assessment during therapy and 
for early outcome prediction is discussed.
Radiation Therapy  
Modalities in Gynecologic Cancer
Therapeutic radiation plays an integral part 
in the multimodality treatment of patients 
with gynecologic cancers (Tables 1, 2). Sev-
eral radiation-based modalities, including 3D 
conformal external beam radiation therapy, 
intensity-modulated radiation therapy (IMRT), 
and brachytherapy (implant radiation), as well 
as novel stereotactic delivery approaches, have 
been incorporated into the paradigm for treat-
ment of gynecologic cancers. It is important for 
radiologists to understand the radiation therapy 
options for the specific types of gynecologic can-
cers and their relevant clinical information, such 
as clinical staging, to optimize the role of imag-
ing at various times in the treatment.
women in the developing world; cervical cancer 
led to approximately 275,000 deaths worldwide 
in 2008, about 88% of which occurred in devel-
oping countries (2). Although ovarian cancer is 
less common, it is fatal much more often than 
any other gynecologic tumor. Similarly, vaginal 
and vulvar cancers continue to pose a serious 
health threat worldwide.
Radiation therapy has played an important 
role in the treatment of gynecologic cancers. 
Concurrent advances in tumor imaging and 
treatment delivery technologies have spawned 
a paradigm shift in radiation therapy from two-
dimensional to three-dimensional (3D) targeted 
treatment planning. This shift has profoundly 
changed the field of radiation oncology in the 
past 10–15 years.
Simultaneously, progress with both surgical 
techniques and systemic chemotherapy has im-
proved treatment outcomes with the use of mul-
timodality therapy. For these three key treatment 
modalities (radiation therapy, surgery, and che-
motherapy), advanced imaging plays an essential 
role in the diagnosis and treatment of gynecologic 
cancers with a multimodality therapy strategy. Al-
though imaging is of great importance in detect-
ing lesions and differentiating cancer from other 
etiologies, the contributions of imaging to medi-
cal, surgical, and radiation therapy change once 
the definitive tissue diagnosis had been made 
with surgical or imaging-guided biopsy. After the 
diagnosis is made, the focus of tumor imaging 
shifts to staging of the disease, delineation of tu-
mor extent for treatment planning and delivery, 
and monitoring response.
From a historical perspective, radiology and 
radiation oncology have a unique past. After 
divergent paths for decades, these two distinct 
specialties are becoming more closely related 
to each other for the optimal treatment of can-
cer. Advanced imaging is essential to radiation 
Table 1: Roles of Chemotherapy and Radiation Therapy in the Treatment of Gynecologic 
Cancers in Relationship to Surgery
Type of  Therapy Description of Therapy
Primary (definitive) 
therapy
A course of radiation therapy or chemotherapy (or both) without any sur-
gery, in which the goal of treatment is curative
Neoadjuvant therapy A course of radiation therapy or chemotherapy (or both) administered be-
fore surgery with the aim of augmenting the surgical outcome
Adjuvant therapy A course of radiation therapy or chemotherapy (or both) administered after 
surgery with the aim of eradicating microscopic locoregional (radiation 
therapy) or distant (chemotherapy) residual cancer cells
Palliative therapy Typically, a short course of radiation therapy or chemotherapy (or both) 
with the aim of reducing cancer symptoms such as pain or obstruction; 
typically, the patient has stage IV cancer, and cure is not possible
1064 July-August 2014 radiographics.rsna.org
is performed by first determining the dose objec-
tives for the tumor target, as well as the normal 
tissues (normal tissue constraints). With the use 
of iterative algorithms and cost functions, inverse 
planning can be used to create a set of fluence 
maps for each beam angle, which result in a dose 
distribution that conforms to the predetermined 
dose objectives for target and normal tissues (3). 
Figure 1 shows an example of IMRT treatment 
beam angles and the resulting isodose distribu-
tion in the axial, coronal, and sagittal planes.
IMRT-based treatment planning further 
improves the ability to conform the treatment 
volume to concave or highly complex tumor 
shapes, thereby delivering a higher dose to the 
target with less toxicity to normal tissues. The 
robustness of IMRT for the treatment of cervi-
cal and endometrial cancer across institutions 
has been recently shown in the results from a 
multi-institutional study (4), and the technique is 
now widely accepted. The preciseness of IMRT 
requires high-quality imaging studies; and often 
CT, dual-modality imaging with positron emis-
3D Conformal Radiation Therapy
Among the external beam radiation modalities, 
in 3D conformal radiation therapy, the profile of 
each radiation beam is shaped to fit the profile 
of the target from a beam’s-eye view by using a 
multileaf collimator and a variable number of 
beams. When the treatment volume conforms 
to the shape of the target, the relative toxicity of 
radiation to the surrounding normal tissues is 
reduced, which allows a higher dose of radiation 
to be delivered to the tumor than nonconformal 
techniques would allow. 3D conformal radiation 
therapy is considered a minimum standard for 
delivery of external beam radiation for treatment 
of gynecologic cancer.
Intensity-modulated Radiation Therapy
IMRT advances one step beyond 3D conformal 
radiation therapy by using inverse treatment 
planning by modulating the beam’s intensity. The 
intensity of the radiation dose is elevated in the 
areas of the target and is decreased in the neigh-
boring normal tissues. Inverse treatment planning 
Table 2: Radiation Therapy for Gynecologic Cancers




Therapy Area Treated with External Radiation Therapy Brachytherapy Group
Cervix
 I–IIA Adjuvant* Pelvic with or without paraaortic nodes Selected patients
 IIB–IVA† Primary Pelvic with or without paraaortic nodes All patients
 IVB, recurrent Palliative Multiple sites NA
Endometrium
 I–II Adjuvant Pelvic with or without paraaortic nodes Selected patients
 IIIA–IVA Adjuvant Pelvic with or without paraaortic nodes Selected patients
 Medically  
 inoperable  
 (all stages)‡
Primary Pelvic with or without paraaortic nodes All patients
 Recurrent Primary Pelvic with or without paraaortic nodes All patients
 Metastatic Palliative Multiple sites NA
Vagina
 I–IIA Adjuvant Pelvic with or without paraaortic nodes, inguinal Selected patients
 IIB–IVA Primary Pelvic with or without paraaortic nodes, inguinal All patients
 Metastatic Palliative Multiple sites NA
Vulva
 I–II Adjuvant Pelvic with or without paraaortic nodes Selected patients
 Metastatic Palliative Multiple sites NA
Ovary
 Recurrent Palliative Pelvic with or without paraaortic nodes NA
 Metastatic Palliative Multiple sites NA
Note.—NA = not applicable. 
*Primary radiation therapy if not suitable for surgery. 
†This group includes selected patients with stage IB2 cancer. 
‡Medically inoperable because of comorbidities.
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Figure 1. IMRT in a woman with cervical cancer. (a–c) Axial (a), coronal (b), and sagittal (c) views of treatment 
planning computed tomography (CT) show dose distribution with IMRT for cervical cancer. (d) 3D reconstruction 
with beam paths shows the use of multiple beam angles to achieve the fused dose distribution to focus on the plan-
ning target volume (PTV) (red area) and reduce the dose to the surrounding normal structures.
sion tomography (PET) and CT (PET/CT), and 
magnetic resonance (MR) imaging are all used for 
the purpose of treatment planning.
Stereotactic Body Radiation Therapy
Stereotactic body radiation therapy refers to stereo-
tactically delivered radiation treatments within 
extracranial body sites. Because stereotactic body 
radiation therapy delivers only a few high-dose 
treatments (hypofractions) and applies highly fo-
cused radiation dose distributions to a relatively 
small and well-defined tumor target, stereotactic 
body radiation therapy requires extremely de-
tailed imaging studies, real-time monitoring of 
imaging, rigid immobilization devices, and, in 
some cases, respiratory motion control. Even 
though stereotactic body radiation therapy has 
not been commonly used in treating gynecologic 
cancers, its clinical efficacy for the treatment of 
spine, lung, and liver lesions generated great in-
terest in the incorporation of this new treatment 
modality into curative and palliative treatment 
regimens for gynecologic malignancies (5,6); and 
stereotactic body radiation therapy has been used 
successfully for primary and recurrent gyneco-
logic cancer. Stereotactic body radiation therapy 
can be performed as 3D conformal radiation 
therapy or IMRT. Because of the extremely high 
doses delivered during stereotactic body radiation 
therapy, more stringent dosimetric, mechanical, 
and imaging quality assurance measures are criti-
cal. Onboard imaging is also essential to ensure 
3D target alignment before each treatment.
Imaging for Pretreatment  
Staging and Prognosis Assessment
Tumor staging, including the tumor volume and 
the extent of involvement, is essential to deter-
mine the prognosis, triage the therapy options, 
and design a multimodality treatment strategy. 
For decades, clinical staging of gynecologic can-
cers has been based on the International Fed-
eration of Gynecology and Obstetrics (FIGO) 
staging system. FIGO staging relies on clinical 
palpation and radiographs alone, a combina-
tion that poses inherent limitations in assessing 
the tumor volume, the involvement of adja-
cent tissues, the spread of disease to regional 
lymph nodes, and the distant metastatic sites 
in patients with gynecologic cancer (7,8). The 
historical reason why FIGO staging excludes 
advanced imaging data and relies exclusively on 
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the findings at clinical examination is because 
of the high prevalence of gynecologic cancers 
in the developing world and the lack of imag-
ing resources in these geographic areas. FIGO 
staging has been reported to underestimate the 
stage in 20%–60% of the patients with cervical 
cancer, compared with surgical correlation (9). 
This partly explains why great variations of local 
recurrence and survival rates exist within each 
FIGO stage category (10). Despite its error-
prone methodology, FIGO staging remains the 
current worldwide standard of practice. There-
fore, a more accurate noninvasive method, in-
cluding advanced imaging, is urgently needed to 
improve the tumor staging.
With the improvement of the spatial and tem-
poral resolution to provide the much-needed 
anatomic detail and functional imaging capability, 
the advanced 3D tumor cross-sectional imaging 
modalities have greatly enhanced the efficacy in 
assessing tumor volume and the extent of involve-
ment, and thus these advanced modalities allow 
further improvement in staging compared with the 
FIGO-based staging assignments. With the im-
provement in tumor delineation, the advanced im-
aging has become an integral part of image-guided 
targeted treatment planning and precise dose de-
livery for patient-centered individualized radiation 
therapy for gynecologic cancers (11,12).
CT Imaging
For decades, CT imaging has been an invaluable 
imaging modality for the treatment of gyneco-
logic cancers, to identify regional involvement in 
pelvic and paraaortic lymph nodes and distant 
metastatic disease to the liver, lungs, bones, and 
others structures. To date, CT remains the most 
widely used diagnostic imaging modality for stag-
ing gynecologic cancer worldwide and remains 
the most used imaging modality for radiation 
therapy treatment planning and for targeting 
dose delivery. However, CT is limited in delineat-
ing the extent of tumor involvement within the 
uterus because of the lack of soft-tissue contrast 
between the tumor and the normal uterine tissue, 
which is critical information needed for the treat-
ment of gynecologic cancers (13).
MR Imaging
The actual tumor size, a well-established prog-
nostic criterion in cervical cancer (10,14), is 
best assessed with MR imaging (15,16). With its 
superior soft-tissue contrast, MR imaging has 
been shown to be an excellent imaging modality 
to delineate the intrauterine tumor involvement 
in cervical and uterine cancer. In surgical-imag-
ing correlation studies, MR imaging is reported 
to provide better staging of early-stage tumors, 
compared with staging from clinical examinations 
(15–17). MR imaging–based 3D tumor volume 
measurement correlates well with histologic find-
ings obtained from digitized giant tissue sections, 
showing a 98% correlation (18), and attesting 
to a high accuracy in delineating tumor extent 
within the uterus in cervical cancer.
In the staging evaluation of cervical cancer, CT 
and MR imaging are generally equivalent for the 
assessment of lymph node and metastatic involve-
ment, but MR imaging is superior in delineating 
tumor extent within the uterus and direct exten-
sions of tumor to adjacent pelvic tissues (19,20), 
including bladder invasion, parametrial extension, 
and rectal and perirectal involvement. Ancillary 
findings that may or may not be related to the 
tumor but can influence the treatment approach, 
such as distortion or retroversion of the uterus, 
uterine fibroids, ovarian findings, and other pelvic 
abnormalities, can be readily evaluated with MR 
imaging. In addition, vaginal extension can be ac-
curately delineated with MR imaging (21).
In endometrial cancer, MR imaging with a 
gadolinium-based contrast material provides 
excellent assessment of the extent of myometrial 
and cervical invasion of the tumor, as well as 
extrauterine extension (22,23), and contrast-
enhanced MR imaging is the imaging modality 
of choice for such assessment. Differentiation 
between endometrial and cervical primary ad-
enocarcinomas, a task that could be clinically and 
histologically challenging, can be performed with 
MR imaging (24).
In vaginal cancer, MR imaging is invaluable 
for delineating the extent of tumor invasion into 
the vaginal wall and paravaginal tissues. Such in-
vasion critically influences the triage of treatment 
options and also the individualized treatment 
planning during radiation therapy.
PET/CT Imaging
The staging of cervical cancer has been further 
advanced by the introduction of PET/CT imag-
ing. Most often, the biologically active molecule 
chosen for PET is fluorine 18 fluorodeoxyglucose 
(FDG), an analog of glucose. The concentrations 
of tracer imaged show tissue metabolic activity in 
terms of regional glucose uptake. Although PET/
CT of cervical cancer has been studied more 
extensively than PET/CT of other gynecologic 
neoplasms in the peer-reviewed medical literature, 
PET/CT is also gaining acceptance in the stag-
ing of other gynecologic malignancies, including 
vaginal cancer and vulvar cancer. FDG PET/CT 
provides the most accurate assessment of pelvic 
and paraaortic lymph node involvement. Tumor 
involvement in these lymph node regions is known 
to be difficult to control with the combination of 
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radiation therapy and chemotherapy alone, and 
such involvement is generally associated with 
much-reduced overall survival. Although PET/
CT findings are not included in the FIGO staging 
system, they have been used increasingly as a stag-
ing tool and have become critically important for 
multimodality therapy planning in patients with 
gynecologic cancer (25,26).
Recently, the American College of Radiology 
Appropriateness Criteria for pretreatment evalua-
tion and follow-up of various gynecologic cancers 
have been published and are freely available at 
the American College of Radiology’s Web site 
(www.acr.org). This information is of great value 
for practitioners in choosing appropriate imaging 
modalities for the assessment of cervical cancers 
and endometrial cancers (27–29).
Principles of Therapy and Role  
of Imaging in Gynecologic Cancer
Cervical Cancer
In cervical cancer, accurate staging is critical for 
appropriate treatment selection and treatment 
planning. Imaging, including CT, MR imaging, 
and PET/CT, plays an important role in (a) re-
fining the tumor staging and target delineation, 
(b) monitoring therapy response, and (c) pro-
viding an early prediction of ultimate treatment 
failure, as well as a basis for adaptive therapy 
(Table 3).
A substantial proportion of cervical cancer 
patients are initially diagnosed with stage IIB–
IVA disease, for which the combination of de-
finitive chemotherapy with radiation therapy is 
the standard of care. Radiation therapy for this 
disease group consists of pelvic external beam 
radiation and brachytherapy (implant radiation). 
Brachytherapy is a critical therapy component 
to cure advanced cervical cancer. Brachytherapy 
provides a localized high-dose radiation boost to 
the cervix and uterus through implanted special-
ized brachytherapy applicators that require close 
and individualized integration with the external 
beam radiation to achieve the maximal effect 
of radiation to the residual tumor. The evolu-
tion from conventional brachytherapy with two-
dimensional treatment planning to 3D image-
guided brachytherapy has enabled higher and 
more conformal dose delivery. Early data suggest 
that tumor control may be further improved with 
image-guided brachytherapy (11,30). This change 
marks a paradigm shift in brachytherapy similar 
to the earlier advances in external beam radia-
tion therapy from conventional two-dimensional 
radiation to 3D conformal radiation therapy and 
IMRT delivery. Since 1999, concurrent cisplatin-
based chemotherapy has been incorporated into 
the course of radiation therapy because data from 
multiple randomized studies had demonstrated 
decreased tumor recurrence rates and improved 
survival with the combined chemotherapy and ra-
diation therapy, compared with radiation therapy 
alone (31).
Patients with stage I–IIA cervical cancer are 
treated with radical hysterectomy and pelvic 
lymphadenectomy or with definitive radia-
tion therapy if they are deemed poor surgical 
candidates (Table 2). Adjuvant postoperative 
radiation therapy is recommended for patients 
with a combination of high-risk histopathologic 
features, such as deep invasion of tumor into 
the cervix, lymphovasular space invasion, and 
tumor size more than 4 cm in diameter (32,33). 
Adjuvant chemoradiotherapy is recommended 
for patients with positive tumor margins, para-
metrial invasion, or involved pelvic lymph nodes 
(34). One exception is patients with stage IB2 
disease. Although their disease is amenable to 
surgical cure, most of them would need postop-
erative radiation therapy, and therefore definitive 
chemoradiotherapy is commonly recommended 
Table 3: Role of Imaging for Cervical Cancer
Pretherapy staging
CT: local pelvic extent, lymph node metastases, 
distant metastases
MR imaging: tumor definition within the cervix 
or uterus, lymph node metastases, distant 
metastases
PET/CT: distant metastases
External beam radiation therapy planning
CT: delineation of tumor target, lymph nodes, 
normal tissues, establishment of clinical target 
volume (CTV) and PTV
MR imaging: delineation of tumor within cer-
vix or uterus, vaginal extension, parametria, 
lymph nodes
Brachytherapy planning
Ultrasonography (US): intraoperative US-guid-
ed brachytherapy applicator insertion
CT: delineation of brachytherapy applicator, 
uterus, normal tissues for image-guided 
brachytherapy
MR imaging: delineation of tumor within cervix, 
uterus, or pelvis for image-guided brachyther-
apy; establishment of CTV and PTV; delinea-
tion of normal tissues, positional abnormali-
ties (retroflexion, retroversion), fibroids
Response assessment and outcome prediction
MR imaging: tumor volumetric response; func-
tional changes (dynamic contrast material– 
enhanced and diffusion-weighted MR imag-
ing) intra therapy, posttherapy
PET/CT: primary tumor, lymph node involve-
ment, posttherapy
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Figure 2. Diagram of the treatment algorithm for cervical cancer, showing the 
role of multimodality imaging. The treatment algorithm shows how tumor staging 
that is based on MR imaging and PET/CT helps identify patients for lymph node 
(LN) dissection and debulking of involved nodes. The robotic lymph node dis-
section technique allows rapid postoperative recovery and an expeditious start of 
definitive radiation therapy and chemotherapy, with radiation target volumes tailored 
according to molecular imaging and the surgical and histopathologic findings.
for these patients (35). Patients with distant 
hematogenous spread of disease (stage IVB) are 
treated mainly with palliative chemotherapy, and 
palliative radiation therapy may be used to treat 
local recurrence and complications that are not 
responsive to the treatment.
Surgery is not only the primary treatment 
for early-stage cervical cancer, but surgery also 
plays an important role in the management of 
pelvic or paraaortic lymph node involvement 
in all stages of cervical cancer. Involved lymph 
nodes are challenging to control with radiation 
therapy, and surgical resection could lead to a 
delay in therapy. Recently, minimally invasive 
robotic surgery has provided a new means to 
address this challenge by facilitating resection 
and allowing fast postoperative recovery. Ro-
botic surgery is becoming increasingly available 
for gynecologic malignancies and allows better 
intraoperative visualization and improved ergo-
nomics. Robotic surgery achieves overall tumor 
control (36,37) similar to that with laparotomy 
but with decreased blood loss, fewer wound 
complications, and a shorter recovery period 
(36). In patients with cervical cancer, the rapid 
postoperative recovery achieved with robotic 
surgery for lymph node dissection or debulking 
allows earlier institution of definitive radiation 
therapy or chemotherapy (or both) within days 
of the procedure, as compared with patients who 
undergo conventional laparotomy for lymph 
node dissection. An integrated algorithm used 
at our institution includes molecular imaging to 
identify involved lymph nodes, robotic lymph 
node dissection, and definitive therapy (Fig 2). 
This algorithm illustrates the importance and 
benefits of a judicious and individualized combi-
nation of imaging modalities to enable an inte-
grated treatment approach.
Endometrial Cancer
In endometrial cancer, stage I disease prevails, 
and most patients are treated with surgery, in-
cluding hysterectomy and lymph node sampling 
or dissection, either with laparotomy or, increas-
ingly, with a robotic approach (36,37). However, 
postoperative radiation therapy is required for 
patients with stage I–II endometrial cancer and 
histopathologic high-risk features for recurrence, 
such as high-grade tumor, outer one-third or 
one-half myometrial invasion, lymphovascular 
space invasion, involvement of the cervix or ad-
nexa, or older age (>70 years), as reported in the 
findings of several randomized trials (38,39). In 
patients with surgical stage III and IV endome-
trial cancer, chemotherapy and volume-directed 
radiation therapy are commonly used.
The role of imaging is the delineation of the 
postoperative target and normal tissue struc-
tures for conformal treatment planning, to 
reduce the dose and toxicity to normal tissue 
(Table 4). In patients with the less-common 
advanced endometrial cancer, imaging plays an 
important role in the assessment of the extent of 
involvement of pelvic structures, lymph nodes, 
and metastatic sites.
RG • Volume 34 Number 4 Xu-Welliver et al 1069
Primary radiation therapy alone without sur-
gery is used as the curative treatment modality 
for patients with “medically inoperable” disease 
because many patients with endometrial cancer 
present with severe comorbidities that preclude 
surgical therapy. Radiation therapy in this set-
ting again involves both pelvic external beam 
radiation therapy and brachytherapy. External 
beam radiation therapy targets the uterus, cer-
vix, upper portion of the vagina, pelvic lymph 
nodes, and other involved areas. Intracavitary 
brachytherapy with specialized intracavitary ap-
plicators is designed to deliver a high-dose boost 
to the involved uterine cavity; and further tar-
geted radiation may be delivered to other areas 
of involvement, requiring image-guided dose de-
livery. Imaging plays an important role in these 
patients, including (a) CT for staging of tumor 
extent and target delineation for external beam 
radiation therapy; (b) MR imaging for assess-
ment of tumor extent within the uterine cavity, 
particularly diffusion-weighted MR imaging 
(40), and response monitoring; and (c) intraop-
erative US to guide insertion of brachytherapy 
applicators.
Vaginal Cancer
Vaginal cancer is rare and accounts for only 
1%–2% of all gynecologic malignancies. Imaging 
plays an important role in the delineation of tumor 
involvement for treatment planning, particularly 
for the assessment of regional and distant metas-
tases (Table 5). In vaginal cancer, the treatment 
relies largely on radiation therapy because most 
vaginal tumors are not amenable to surgical resec-
tion. Even in small stage I vaginal cancers (tumor 
confined to a limited portion of the vagina), which 
are treated with surgery, radiation therapy is usu-
ally required after surgery, especially for close or 
involved margins. The radiation therapy for stage 
II or higher-stage vaginal cancers includes defini-
tive external beam radiation therapy to the pelvis, 
often with chemotherapy, with or without inclu-
sion of the inguinal lymph nodes, as well as highly 
individualized interstitial or intravaginal brachy-
therapy, in which MR imaging is helpful in delin-
eating the tumor target (Table 5) (41).
Vulvar Cancer
In vulvar cancer, the primary treatment is radi-
cal surgery (radical vulvectomy and lymph node 
dissection). Molecular imaging has contributed 
to tumor staging in high-risk disease (Fig 3) 
and to an innovative approach to sentinel node 
dissection. For radiation therapy, imaging plays 
an important role in delineating the extent of 
disease involvement for treatment planning, par-
ticularly for the assessment of regional and dis-
tant metastases. However, radiation therapy has 
an essential adjuvant role in women with lymph 
node involvement or large tumors with positive 
margins. The benefit of the addition of radiation 
therapy after radical vulvectomy and inguinal 
lymphadenectomy in inguinal node–positive 
patients was demonstrated in the Gynecologic 
Oncology Group’s GOG-36 trial (42); adjuvant 
Table 4: Role of Imaging for Endometrial 
Cancer
Pretherapy staging (for advanced tumors)
CT: local pelvic extent, lymph node metastases, 
distant metastases
MR imaging: tumor definition within the uterus, 
myometrial invasion, delineation of primary 
tumor (uterus or cervix), lymph node metas-
tases, distant metastases
External beam radiation therapy planning
CT: delineation of tumor or postoperative tar-
get, lymph nodes, normal tissues, CTV, PTV
MR imaging: delineation of tumor within cervix 
or uterus, postoperative target, vaginal exten-
sion, parametria, lymph nodes
Brachytherapy planning
US: intraoperative US-guided brachytherapy 
applicator insertion
CT: delineation of brachytherapy applica-
tor, uterus, normal tissues for image-guided 
brachytherapy
Response assessment and outcome prediction
MR imaging: tumor volumetric response, myo-
metrial invasion, intratherapy, posttherapy
Table 5: Role of Imaging for Vaginal Cancer
Pretherapy staging
CT: local vaginal, pelvic, or vulvar extent; lymph 
node metastases; distant metastases
MR imaging: tumor definition within the vagina, 
vaginal wall invasion, lymph node metastases, 
distant metastases
External beam radiation therapy planning
CT: delineation of tumor, lymph nodes, normal 
tissues, CTV, PTV
MR imaging: delineation of tumor, lymph 
nodes, normal tissues, CTV, PTV
Brachytherapy planning
CT: delineation of brachytherapy applicator, va-
gina, normal tissues for image-guided brachy-
therapy
MR imaging: delineation of brachytherapy ap-
plicator, vaginal invasion, normal tissues for 
image-guided brachytherapy
Response assessment and outcome prediction
CT: tumor response, posttherapy
MR imaging: tumor response, posttherapy
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Figure 3. Molecular imaging for tumor staging in a woman with high-risk vulvar cancer. (a) Coronal 
fused PET/CT image obtained after resection of vulvar cancer shows increased avidity of a tumor 
mass in the left chest wall. This finding profoundly changed the treatment approach from treat-
ment with curative intent to palliative therapy. (b) Coronal fused PET/CT image obtained after 
chemotherapy shows decreased avidity of the chest wall mass, which indicates improvement, but 
also shows development of a metastasis to the spine.
radiation therapy decreased groin recurrence 
(5% vs 24%) and improved the 2-year overall 
survival (68% vs 54%). An overview of vulvar 
cancer imaging is presented in Table 6.
Ovarian Cancer
Although ovarian cancer is primarily treated surgi-
cally and with chemotherapy, radiation therapy 
is useful in the palliation of regional focal disease 
(43). CT, as well as PET/CT (44), is the base for 
the delineation of recurrent ovarian cancer lesions 
for radiation therapy planning. In addition, admin-
istering low-dose radiation therapy to enhance the 
effectiveness of chemotherapy is being explored as 
a novel approach (5). The role of imaging is largely 
limited to CT, as detailed in Table 7.
Table 6: Role of Imaging for Vulvar Cancer
Pretherapy staging (in advanced tumors)
CT: local vulvar, vaginal, or pelvic extent; lymph 
node metastases; distant metastases
External beam radiation therapy planning
CT: delineation of tumor, lymph nodes, normal 
tissues, CTV, PTV
Brachytherapy planning
CT: delineation of brachytherapy applicator, 
vulva and vagina, normal tissues for image-
guided brachytherapy
Response assessment
CT: tumor response, posttherapy
Table 7: Role of Imaging for Ovarian Cancer
Pretherapy staging
CT: abdominal tumor extent, lymph node me-
tastases, pleural effusion, distant metastases
US: detection of ovarian cancer, staging (solid 
components or ascites)
External beam radiation therapy planning (pal-
liative)
CT: delineation of tumor, lymph nodes, normal 
tissues, CTV, PTV
Response assessment
CT: tumor response to chemotherapy (in con-
junction with tumor markers)
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Figure 4. Principles of target definition in radiation therapy planning. Diagram 
(top) and axial CT image (bottom) illustrate the definitions of the GTV (blue), 
CTV (green), and PTV (red).
Principles of Radiation Therapy  
and the Role of Multimodality Imaging
Radiation oncologists rely on their radiology col-
leagues to help delineate tumor extension and the 
boundaries of tumor involvement, a task that can 
be challenging in pelvic tumors. Imaging infor-
mation for the radiation oncologist (Tables 3–7) 
extends well beyond the diagnostic purpose. Imag-
ing paradigms extend from diagnostic, diagnostic/
targeting, theragnostic, and response assessment 
to the novel concept of predictive imaging. The 
diagnostic paradigm is used for staging and the 
assessment of disease extent and crosses into the 
targeting paradigm, in which precise delineation 
of the tumor volume and extensions is critical. 
Imaging-based response monitoring and response 
assessment allow adaptation of the treatment regi-
men to improve tumor control and survival.
Imaging for Tumor Targeting  
in Radiation Therapy Planning
Killing tumor cells with ionizing radiation is a func-
tion of the total radiation dose to the tumor target 
and the fraction size (the dose of each individual 
daily treatment in the course of radiation therapy). 
The dose required for tumor control (tumor control 
probability) is proportional to the logarithm of the 
number of clonogenic cells in the tumor. Therefore 
the dose required to control a palpable or visible 
tumor mass is higher than that required for sub-
clinical extensions of tumor, such as microscopic 
involvement or disease below the level of clinical 
or imaging detection. The challenge is to deliver a 
maximal radiation dose to the tumor target while 
minimizing the dose received by normal radiosensi-
tive tissues in the surrounding areas. To minimize 
radiation toxicity and complications, one must 
have as much information as possible with regard to 
the extent of tumor involvement and whether it has 
involved any neighboring organs.
Definition of Target Structures
One of the most important questions for a ra-
diation oncologist in planning the treatment 
volumes for imaging-based and image-guided 
therapy in patients with gynecologic cancer is de-
fining the target. The planning of treatment with 
radiation therapy has been revolutionized by the 
ability to delineate tumors and adjacent normal 
structures in three dimensions by using special-
ized CT scanners or MR imagers equipped with 
set-up lasers and software (45) to transfer the im-
aging and planning information to the planning 
software and subsequently to the linear accelera-
tor for delivery of treatment. CT or MR imaging 
or both are performed in the treatment position 
with immobilization of the patient. Radiopaque 
fiducial marks are placed according to the lasers 
and are used as reference points on the patient’s 
skin to ensure daily reproducible positioning for 
the delivery of treatment.
Local and regional tumor control (ie, the control 
of the tumor and its draining lymph node regions 
that are at risk for involvement) depends on the 
precise delineation, targeting, and delivery of the 
required radiation dose to grossly detectable (by 
palpation or imaging) tumor and microscopic (sub-
clinical) tumor, respectively. Tumor control depends 
on accurate target delineation, which is based on 
the strict definition of tumor target volumes (Fig 
4). Tumor target volumes are based on patterns of 
disease spread, correlative surgical and pathologic 
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Figure 5. CT-based target delineation in a 
woman with gynecologic cancer, with color con-
touring of the target structures and the normal 
structures. (a, b) Axial (a) and sagittal (b) CT 
images show contouring of the target structure, the 
uterus (green contour). (c–e) Axial (c), coronal (d), 
and sagittal (e) CT images show contouring of the 
target regional lymph nodes (red contour) (Fig 5 
continues).
Target Delineation
On the basis of these principles, the GTV and 
CTV are contoured on each imaging section. 
Figure 5 illustrates the contouring of the uterus 
and tumor extensions in the pelvis (GTV) (Fig 
5a, 5b; area within green contour) and the con-
touring of the external iliac and common iliac 
information, and the principles of radiation biology, 
which provides the basis for the radiation dose pre-
scription in radiation therapy planning.
The gross target volume (GTV) denotes all de-
monstrable tumors (demonstrable with clinical 
or imaging-based detection). The GTV is often 
defined with multimodality imaging such as 
PET/CT fusion or MR imaging (or both). The 
clinical target volume (CTV) denotes the GTV 
and microscopic (“subclinical”) tumor involve-
ment. The GTV and CTV provide the basis 
for designing the planning target volume (PTV), 
which includes the CTV and margins for geo-
metric uncertainties relating to patient motion 
and inherent set-up inaccuracy during the daily 
delivery of radiation therapy.
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Figure 5. (continued). (f–i) Coronal (f), axial (g, h), and sagittal (i) CT images show contouring of 
pertinent normal structures. Typical radiation dose requirements for the target structures and dose 
limits for the normal structures are 85 Gy or more for the tumor and uterus (aqua contour on f, lower 
arrow on i), 45–66 Gy for the lymph nodes (red contour, upper arrow on i), maximum dose of 25 Gy 
or less for each kidney (left kidney, green contour on f; right kidney, dark blue contour on f), maximum 
dose of 45 Gy or less for the spinal cord and cauda (hot pink contour on f, i), 45 Gy or less for the blad-
der (yellow contour on g, i), less than 40 Gy for the rectum (reddish brown contour on g), and 50 Gy or 
less for the bowel (reddish brown contour on h).
lymph nodes (Fig 5c–5e; red contour); together 
the two areas of contouring represent the CTV 
on the treatment planning CT in a patient 
with cervical cancer. The PTV (Fig 5f, 5i; area 
shaded with red) is then derived, which provides 
the basis for beam modeling and dosimetry.
Normal tissue structures are also contoured for 
the planning process because the radiation dose to 
these structures must be reduced as much as pos-
sible (Fig 5f–5i). The degree of radiation exposure 
to normal structures is directly correlated with 
complications in the normal tissue. Guidelines for 
target delineation of gynecologic pelvic tumors for 
CT- and MR imaging–based treatment planning 
have been published recently (46). Target delinea-
tion is generally performed on axial imaging sec-
tions; software allows real-time coronal and sagit-
tal reconstructions to aid the contouring process.
Multimodality imaging has entered into the 
treatment planning process in patients with 
cervical cancer. In addition to the standard CT 
for radiation therapy planning, the GTV is fre-
quently refined with MR imaging (Fig 6) (46) 
and PET/CT (Fig 7).
PET/CT-based delineation of involved pelvic 
lymph nodes has improved targeting and delivery 
of higher tumoricidal doses to these regions of 
tumor involvement. Figure 7 shows image coreg-
istration between the treatment planning with CT 
and PET/CT. The metabolic activity of involved 
pelvic lymph nodes has been delineated on the 
PET/CT image and is projected onto the coreg-
istered planning CT image. This process allows 
precise determination of the tumor-involved pelvic 
lymph node region and enables radiation dose in-
tensification through the high-precision targeting 
of such involved structures.
Figure 5f–5i shows the complete process of de-
lineation of the GTV, CTV (accounting for poten-
tial microscopic tumor spread), and PTV. The dose 
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Figure 7. Multimodality imaging-based target delineation in a woman with gynecologic cancer. Axial pelvic CT 
image acquired for treatment planning is coregistered with FDG PET images (a) to allow the delineation of a hy-
permetabolic external iliac lymph node, as shown on b (purple contour). This high-precision delineation allows tar-
geting of the involved lymph nodes with a higher radiation dose.
Figure 6. MR imaging–based target delineation in a woman with cervical cancer. Axial 
(a) and sagittal (b) MR images show that MR imaging–based planning allows contouring 
of the cervical tumor and GTV (red contour), cervix (pink contour), vagina (yellow con-
tour), uterus (dark blue contour), parametria (green-dotted contour on a, aqua contour 
on b), bladder (purple contour on b), and large bowel (orange contour on b). Arrows on 
a point to the left and right broad ligaments, and arrowheads on a indicate the uterosacral 
ligaments and mesorectal fascia. (Reprinted, with permission, from reference 46.)
constraints (imposed dose limits) to normal tissues 
are also represented. High doses to the uterus and 
tumor (≥85 Gy) and to tumor-involved lymph 
nodes (60–66 Gy) and moderate doses to the areas 
at risk for microscopic tumor involvement (45–50 
Gy) are in stark contrast to the limitations posed 
for radiosensitive critical normal tissues, including 
the small bowel, kidneys, and spinal cord, and for 
moderately radiosensitive structures, including the 
rectum and bladder (Fig 5f–5i).
Beam Modeling and Dosim- 
etry for Radiation Therapy Delivery
The fundamental challenge is how to deliver the 
required tumoricidal dose to the target structures 
and also protect sensitive normal tissues from dose 
exposure, thereby minimizing the risk of complica-
tions in normal tissue. Techniques such as 3D con-
formal radiation therapy, IMRT, and stereotactic 
body radiation therapy are used to achieve the dose 
distribution for the individual clinical situation.
Brachytherapy
Although traditionally prescribed on the basis of 
two-dimensional dose points (47), methods of re-
fined imaging-based dose planning have only been 
introduced recently in gynecologic brachytherapy. A 
breakthrough has been achieved with the introduc-
tion of brachytherapy applicators that are compat-
ible with CT and MR imaging, which now enable 
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the use of image-guided brachytherapy (11,12). For 
image-guided brachytherapy, imaging is performed 
immediately after the insertion of the applicators 
with the applicators in place. High-precision delin-
eation of the tumor target is thus feasible by using 
precise dose computation that allows the individual-
ized target-based 3D conformal treatment planning 
and delivery necessary for brachytherapy.
For the delineation of the actual tumor extent 
within the cervix at the time of brachytherapy, 
MR imaging is the only modality that differen-
tiates tumor from the normal uterus and sur-
rounding pelvic structures (17,18,20). Figure 8 
illustrates the delineation of the target at the time 
of brachytherapy in a patient with endometrial 
cancer. A sample radiology report is proposed 
here as a reference for pretreatment studies (at 
the time of diagnosis) (Table 8).
Morphologic and Functional  
Imaging for Response Assess- 
ment and Early Outcome Prediction
For personalized care in patients with gyneco-
logic cancer, the monitoring of response and the 
prediction of treatment outcome are paramount. 
If treatment failure is not detected until months 
or years after therapy, the salvage treatment op-
tions will be severely limited. Assessing treatment 
response with imaging during the course of radia-
tion treatment may provide a means for early pre-
diction of treatment failure, thus opening an early 
window of opportunity to modify the treatment 
strategy for better outcome. Even though this 
image-based approach to the evaluation of treat-
ment response has not been adopted routinely, it 
has been studied extensively (48).
Role of Anatomic or  
Morphologic Early Re- 
sponse Assessment during Therapy
In addition to tumor pretreatment staging for triag-
ing treatment options, morphologic imaging during 
therapy has an important role for radiation on-
cologists for (a) tumor delineation and measure-
ment of volume regression for response assessment, 
(b) tumor delineation for treatment planning and 
adaptation, (c) tumor delineation for treatment 
planning for brachytherapy, and (d) early outcome 
prediction and potential for adaptive therapy.
Tumor Delineation and Measurement of Volume 
Regression for Response Assessment.—Assess-
ment of the tumor volume and volume regression 
rate of gynecologic cancers poses major chal-
lenges. The diameter-based measurements of the 
RECIST (Response Evaluation Criteria in Solid 
Tumors) guidelines assume elliptical tumor shape 
and linear tumor regression. Although valuable, 
these measurements cannot allow the apprecia-
tion of subtle changes in irregular tumor volumes 
during early treatment (49). Advanced 3D quan-
titative imaging overcomes such challenges. With 
3D contouring of the tumor (Fig 6), which is 
commonly performed during radiation therapy 
planning, precise 3D tumor volume can be de-
rived (17–20). On the basis of the reported 98% 
correlation between the 3D MR imaging–derived 
tumor volume and the 3D-reconstructed histo-
Table 8: Sample Radiology Report for Pre-
treatment Studies (at the Time of Diagnosis)
Tumor size in three dimensions
3D tumor volume upon specific request
Tumor borders (specifically address the following)
Extension to adjacent structures such as parame-
tria (extent of involvement helpful, especially 
in MR imaging report), vagina, uterus (lower 
uterine segment, body, fundus should be speci-
fied with MR imaging report), bladder, rectum, 
or ovaries
Thickness of uterine wall in endometrial cancer 
(at the midpoint of the corpus or at the loca-
tion of abnormality; measure both anterior 
and posterior thickness)
Depth of myometrial invasion (MR imaging, in 
endometrial cancer)
Encasement of vessels
Obliteration of fat planes in cul-de-sac or be-




Presence of fluid within the cavity
Obstruction of endometrial canal
Uterine positioning (flexion and version)
Status of ovaries, such as presence of ovarian 
masses
Abnormal pelvic lymph nodes and their location
Define precise location within each lymph node 
station (ie, distal, proximal, medial, or lateral 
to a point of reference)
Morphology and size in two dimensions
Fixation (ie, obliteration of fat planes surround-
ing the abnormal lymph node)
Paraaortic lymph nodes: exact level or location by 
image numbers
Distant metastasis
Any parenchymal, soft-tissue, bone, or omental 
or peritoneal locations within the field of view
Presence of hydronephrosis and hydroureter, with 
exact level of obstruction if in the field of view
PET/CT additional items to report
Metabolic activity of the described lesions, with 
maximum standardized uptake value (SUVmax) 
for each
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logic tumor volume (18), the tumor regression can 
therefore be precisely measured, and the temporal 
response dynamics of the tumor with time can 
be determined in individual patients. Diagnostic 
radiologists play an essential role in implementing 
high-resolution imaging protocols to achieve high 
lesion-to-background contrast ratios in lesion de-
lineation, radiation therapy planning, response as-
sessment, and hence the potential early prediction 
of treatment outcome.
Figure 8. Role of 
multimodality imag-
ing in the primary 
radiation therapy for a 
woman with stage IB 
endometrial cancer. 
(a) Pretherapy sagittal 
T2-weighted MR im- 
age shows a large tu-
mor filling the endo- 
metrial cavity. (b) Re- 
peat sagittal T2-
weighted MR image 
obtained for brachy-
therapy planning at 
the completion of the 
external beam ra-
diation therapy shows 
excellent response to 
a dose level of 45 Gy 
in 5 weeks of pelvic 
radiation therapy and 
also shows a change 
of the uterine position 
from retroversion (a) 
to mid position (b), 
which is essential 
information for the 
placement of the in-
trauterine Y-tandem 
brachytherapy appli-
cator. The Y-tandem 
applicator is placed 
with US guidance. 
(c, d) Treatment 
planning axial (c) 
and sagittal (d) CT 
images show the 
Y-tandem applicator 
within the contoured 
uterus (pink contour). 
(e, f) Treatment plan-
ning coronal (e) and 
sagittal (f) CT images 
show the brachyther-
apy dose distribution 
by various colored 
isodose lines (yellow, 
light blue, green, red, 
dark blue, and pink, 
with the area within 
the yellow line receiv-
ing the lowest dose 
and the area within 
the pink line with the 
pink shading receiving 
the highest dose).
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Tumor Delineation for Treatment Planning and 
Adaptation.—Tumor delineation (Fig 6) is criti-
cal for intratreatment planning and intratreatment 
adaptation of the PTVs. Changes in tumor volume 
and the configuration of pelvic organs have been 
shown to profoundly alter and shift the PTV and 
consequently the dose coverage for focused ra-
diation therapy techniques, such as IMRT. If the 
PTV can be adapted to both of these changes, the 
tumor targeting may be improved by reducing the 
chance of a geometric miss, and better protection 
of normal tissues may be achieved. The optimal 
frequency for intratreatment imaging and planning 
is an active area of research.
Tumor Delineation for Treatment Planning for 
Brachytherapy.—Evaluation of tumor regres-
sion comes to the forefront in intratreatment 
planning for brachytherapy. Approximately half 
of the therapeutic radiation dose is given with 
brachytherapy, accentuating the importance of 
optimizing the brachytherapy. Only relatively lim-
ited centralized tumors are ideal for intracavitary 
brachytherapy, whereas larger tumors with more 
lateral extension require an interstitial compo-
nent. Refined MR imaging–based tumor delinea-
tion and treatment response assessment have been 
critical for the paradigm change in image-guided 
brachytherapy (Fig 8).
A proposed sample radiology report for intra-
treatment imaging studies is provided (Table 9). 
In addition, a sample radiology report for post-
treatment follow-up studies, which are commonly 
performed to evaluate for clinically suspected 
recurrence, is provided (Table 10).
Outcome Prediction.—At the posttherapy 
follow-up MR imaging, the complete disappear-
ance of a tumor mass 3–6 months after therapy 
is associated with better outcome (17,50). How-
ever, such critical information is available rela-
tively late, which does not allow early therapy 
adaptation. During treatment, the rate of tumor 
regression, quantified with high precision by 
using 3D tumor volumetry, has been found to 
be predictive of treatment outcome in cervical 
cancer patients treated with radiation therapy 
and chemotherapy (50–52). Patients with tumor 
regression to less than 20% of the original 3D 
volume at a radiation dose level of 40–50 Gy 
(4–5 weeks of radiation therapy) had 97% tu-
mor control and a 72% disease-specific survival 
rate, compared with 53% and 50%, respectively, 
with slower tumor regression (50). Similarly, in 
another study, no tumor recurrences were found 
in patients with less than 30% of the original 
volume at a dose level of 30 Gy in approximately 
3–3½ weeks (51).
Functional Imaging for Early Out- 
come Prediction: Predictive Imaging for 
Therapy Adaptation—Future Directions
Dynamic Contrast-enhanced MR Imaging for 
Assessment of Cervical Cancer.—Dynamic con-
trast-enhanced MR imaging provides an in vivo 
imaging biomarker that, through its assessment 
of tumor perfusion, reflects the delivery of oxygen 
and therapeutic agents to the tumor (53,54). 
Both of these factors are critical for the success of 
therapy in patients with cervical cancer (55–57). 
Dynamic contrast-enhanced imaging sequences 
are easy and fast to use within a routine MR imag-
ing examination before, during, and after radiation 
therapy and therefore can be easily incorporated 
into routine practice. Low levels of tissue enhance-
Table 9: Sample Radiology Report for Intra-
treatment Studies
Treatment response (regression or progression 
compared with the pretreatment examination)
Extension to adjacent structures (parametria, 
vagina, uterus, bladder, rectum, ovary, cul-de-
sac, peritoneum)
In endometrial cancer: depth of tumor invasion 
(including changes) and thickness of uterine 
wall (at midpoint of the corpus or at a location 
of abnormality; measure both anterior and 
posterior thickness)
Thickness of residual tumor (especially in vagi-
nal tumors)
3D tumor volume upon specific request
RECIST evaluation upon specific request




Patency of endocervical canal
Uterine positioning (flexion and version)
Lymph node response compared with pretreat-
ment examination
Define precise location within each lymph node 
station (ie, distal, proximal, medial, or lateral 
to a point of reference)
Morphology and size in two dimensions
Fixation (ie, obliteration of fat planes surround-
ing the abnormal lymph node)
Complications: fistula, fluid collections, hydrone-
phrosis, hydroureter, new metastasis
PET/CT additional item to report
Metabolic activity of the described lesions with 
SUVmax for each, as compared with the pre-
treatment examination, is helpful (eg, SUVmax 
of tumor was two times that of the liver, com-
pared with five times before treatment)
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ment at dynamic contrast-enhanced imaging (Fig 
9) (58), which signal poor tumor perfusion and 
hypoxia, have been shown to correlate with unfa-
vorable tumor control and survival in patients with 
cervical cancer (59–61). This predictive information 
can be acquired as early as 2 weeks after the start 
of radiation therapy in patients with cervical cancer 
(60,61). Low perfusion during radiation therapy 
predicts significantly unfavorable tumor control and 
survival (73% vs 100%, P = .006; and 47% vs 79%, 
P = .001, respectively). Assessment at the 2-week 
intratreatment time thus may be more sensitive 
than the pretherapy evaluation (61).
Diffusion-weighted MR Imaging.—The indirect 
assessment of tumor cellularity (62,63) with diffu-
sion-weighted MR imaging provides another phys-
iologic-radiologic correlate to serve as an imaging 
biomarker during radiation therapy. The apparent 
diffusion coefficient from diffusion-weighted MR 
imaging is a measure of the magnitude of diffusion 
(of water molecules) within tissues. A low value 
for the apparent diffusion coefficient indicates that 
the tissue is cellular. Apparent diffusion coefficient 
values in tumors typically increase with successful 
treatment (64), which can be assessed earlier than 
morphologic tumor changes. In recent early clini-
cal experience, investigators have shown that an 
intratreatment increase in the apparent diffusion 
coefficient is associated with improved tumor re-
sponse after chemoradiotherapy for cervical cancer 
(65,66).
The findings of these early studies suggest that 
both dynamic contrast-enhanced MR imaging and 
diffusion-weighted MR imaging show promise as 
functional imaging biomarkers for response moni-
toring and outcome prediction in patients with 
cervical cancer. Dynamic contrast-enhanced MR 
imaging provides the ability to assess tumor perfu-
sion, which is reflective of oxygenation and che-
motherapy delivery; and diffusion-weighted MR 
imaging allows the assessment of tumor cellularity.
Early Outcome  
Prediction for Adaptive Therapy
With the early identification of the subgroup 
of patients at high risk for failure of standard 
therapy, more intensified therapy can be targeted 
to this population. Such risk-tailored person-
alization of care is a stark departure from the 
currently practiced evidence-based approach or 
current clinical trial designs that use therapy in-
tensification indiscriminately for all patients with 
stage IB2–IVA cervical cancer.
Further clinical trials are under way to validate 
the outcome-predictive power of functional MR 
imaging in patients with gynecologic tumors and 
to determine the best method and timing of the 
imaging, so that imaging biomarker–based per-
sonalization of care can be built into the course 
of radiation therapy and chemotherapy by adapt-
ing the regimens of both the radiation therapy 
and the chemotherapy.
Conclusion
To optimize multidisciplinary care for patients 
with gynecologic cancer, radiologists should col-
laborate closely with their radiation oncology 
and gynecologic oncology colleagues and should 
tailor their radiology reports to the needs of the 
treating physicians because high-quality imaging 
has become essential not only for the staging of 
gynecologic malignancies but also for the delin-
Table 10: Sample Radiology Report for Post-
treatment Follow-up Studies (Commonly Per-
formed to Evaluate for Clinically Suspected 
Recurrence)
Answer the pertinent questions asked by clinicians 
because some may be dictated by the clinical 
trial in which the patient is enrolled
Presence of recurrence or progression (or both) 
compared with the most recent examination
Extension of suspected tumor to adjacent  
structures (parametria, fixation to pelvic wall, 
vagina, bladder, rectum, ovaries, cul-de-sac, 
peritoneum)
In endometrial cancer: depth of tumor invasion 
and thickness of uterine wall (at the midpoint 
of the corpus or at a location of abnormality; 
measure both anterior and posterior thickness)
Size of tumor in three dimensions
3D tumor volume upon specific request
RECIST evaluation upon specific request
Please be specific and objective with regard to 
imaging interpretation pertaining to tumor 
progression (eg, patient may have decreased 
tumor size with new enlarged right external 
iliac lymph node)
Presence of tumor necrosis
Uterine findings
Intrauterine fluid
Patency of endocervical canal
Abnormal lymph nodes
Morphology and size in two dimensions
Fixation (ie, obliteration of fat planes surround-
ing the abnormal lymph node)
Complications: fistula, fluid collections, hydrone-
phrosis, hydroureter, new metastasis
PET/CT additional item to report
Metabolic activity of the described lesions with 
SUVmax for each, as compared with the most 
recent examination (eg, SUVmax of the tumor 
is two times that of the liver, which is stable 
compared with the previous examination)
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Figure 9. Dynamic contrast-enhanced MR imaging and tumor control in two women with stage IIB squamous cell 
carcinoma of the cervix. Dynamic contrast-enhanced MR images (left, center on a, b) and dynamic contrast enhance-
ment distribution voxel histograms (right on a, b) of the two women show different heterogeneous dynamic contrast-
enhanced patterns: intense dynamic contrast enhancement of the tumor region (high signal intensity, 10%) in one 
patient (a) and low dynamic contrast enhancement (low signal intensity, 10%) in the other patient (b). The patient in 
a was alive and well 8 years after therapy and had experienced continued tumor control throughout the 8-year follow-
up period, a finding consistent with cure of the cervical cancer. The tumor of the patient in b recurred in the cervix 2 
months after therapy, and she died 6 months after therapy completion. (Adapted, with permission, from reference 58.)
eation of tumor extent for treatment planning 
and delivery, as well as for monitoring of the 
response to therapy.
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Advanced imaging is essential to radiation therapy for (a) the evaluation of the extent of tumor in-
volvement for pretherapy staging and prognostic assessment, (b) tumor delineation for targeting in 
radiation therapy planning, (c) the evaluation of therapy response after or during the course of treat-
ment, and (d) the prediction of early response and outcome, an emerging role that enables potential 
adaptive treatment.
Page 1064
IMRT advances one step beyond 3D conformal radiation therapy by using inverse treatment planning 
by modulating the beam’s intensity. The intensity of the radiation dose is elevated in the areas of the tar-
get and is decreased in the neighboring normal tissues. Inverse treatment planning is performed by first 
determining the dose objectives for the tumor target, as well as the normal tissues (normal tissue con-
straints). With the use of iterative algorithms and cost functions, inverse planning can be used to create a 
set of fluence maps for each beam angle, which result in a dose distribution that conforms to the prede-
termined dose objectives for target and normal tissues (3).
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Stereotactic body radiation therapy refers to stereotactically delivered radiation treatments within extracra-
nial body sites. Because stereotactic body radiation therapy delivers only a few high-dose treatments (hy-
pofractions) and applies highly focused radiation dose distributions to a relatively small and well-defined 
tumor target, stereotactic body radiation therapy requires extremely detailed imaging studies, real-time 
monitoring of imaging, rigid immobilization devices, and, in some cases, respiratory motion control.
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The actual tumor size, a well-established prognostic criterion in cervical cancer (10,14), is best assessed 
with MR imaging (15,16). With its superior soft-tissue contrast, MR imaging has been shown to be 
an excellent imaging modality to delineate the intrauterine tumor involvement in cervical and uterine 
cancer.
Page 1067
Imaging, including CT, MR imaging, and PET/CT, plays an important role in (a) refining the tumor 
staging and target delineation, (b) monitoring therapy response, and (c) providing an early prediction 
of ultimate treatment failure, as well as a basis for adaptive therapy (Table 3).
